Shattuck Labs, Inc. (NASDAQ:STTK) Stock Position Trimmed by Jane Street Group LLC

Jane Street Group LLC decreased its position in Shattuck Labs, Inc. (NASDAQ:STTK) by 46.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,705 shares of the company’s stock after selling 22,703 shares during the period. Jane Street Group LLC’s holdings in Shattuck Labs were worth $90,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Atom Investors LP acquired a new position in shares of Shattuck Labs during the third quarter worth approximately $35,000. Readystate Asset Management LP acquired a new position in Shattuck Labs during the 3rd quarter worth $39,000. The Manufacturers Life Insurance Company acquired a new position in Shattuck Labs during the 2nd quarter worth $67,000. Benjamin Edwards Inc. bought a new position in shares of Shattuck Labs in the third quarter worth $61,000. Finally, MetLife Investment Management LLC increased its holdings in shares of Shattuck Labs by 129.1% during the third quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock valued at $86,000 after purchasing an additional 13,859 shares during the period. Institutional investors and hedge funds own 58.74% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on STTK. Citigroup lowered Shattuck Labs from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $2.00 in a report on Wednesday, October 2nd. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research report on Friday, November 15th. Evercore ISI upgraded Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, November 14th. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.67.

Shattuck Labs Trading Down 5.9 %

Shares of STTK stock opened at $1.12 on Wednesday. The firm’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $2.39. Shattuck Labs, Inc. has a 1 year low of $0.94 and a 1 year high of $11.76. The firm has a market capitalization of $53.47 million, a P/E ratio of -0.73 and a beta of 1.71.

Insider Activity at Shattuck Labs

In related news, Director Redmile Group, Llc acquired 133,371 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was purchased at an average cost of $1.25 per share, with a total value of $166,713.75. Following the acquisition, the director now directly owns 5,539,724 shares of the company’s stock, valued at approximately $6,924,655. The trade was a 2.47 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.50% of the stock is owned by company insiders.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.